

Ysabella Z A Van Sebille

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5173583/publications.pdf>

Version: 2024-02-01

25
papers

1,340
citations

566801

15
h-index

580395

25
g-index

25
all docs

25
docs citations

25
times ranked

1817
citing authors

#	ARTICLE	IF	CITATIONS
1	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2020, 126, 4423-4431.	2.0	540
2	Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1376-1386.	1.9	114
3	Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. <i>International Journal of Cancer</i> , 2016, 139, 2635-2645.	2.3	108
4	Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics. <i>Current Oncology Reports</i> , 2015, 17, 50.	1.8	59
5	ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis. <i>Cancer Treatment Reviews</i> , 2015, 41, 646-652.	3.4	53
6	Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019, 27, 4011-4022.	1.0	51
7	Gut microbiota: implications for radiotherapy response and radiotherapy-induced mucositis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 485-496.	1.4	51
8	Prophylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 187-197.	0.5	43
9	Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. <i>Supportive Care in Cancer</i> , 2020, 28, 5059-5073.	1.0	40
10	TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2767-2779.	1.9	38
11	Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols. <i>Gut Microbes</i> , 2021, 13, 1979878.	4.3	38
12	Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542092849.	0.8	35
13	Toll-like receptor 4 signaling: A common biological mechanism of regimen-related toxicities. <i>Cancer Treatment Reviews</i> , 2015, 41, 122-128.	3.4	34
14	Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. <i>International Journal of Cancer</i> , 2017, 140, 2820-2829.	2.3	27
15	Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer. <i>International Journal of Cancer</i> , 2018, 142, 369-380.	2.3	18
16	Oral-Gut Microbiome Axis in the Pathogenesis of Cancer Treatment-Induced Oral Mucositis. <i>Frontiers in Oral Health</i> , 2022, 3, 881949.	1.2	17
17	Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 1779-1788.	1.0	16
18	Digital education strategies around the world: practices and policies. <i>Irish Educational Studies</i> , 2022, 41, 85-106.	1.5	15

#	ARTICLE	IF	CITATIONS
19	Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 431-434.	1.1	10
20	Use of zebrafish to model chemotherapy and targeted therapy gastrointestinal toxicity. <i>Experimental Biology and Medicine</i> , 2019, 244, 1178-1185.	1.1	10
21	A novel <i>in vitro</i> platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options. <i>Experimental Biology and Medicine</i> , 2016, 241, 1386-1394.	1.1	8
22	Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 152-156.	0.5	6
23	Selective MMP Inhibition, Using AZD3342, to Reduce Gastrointestinal Toxicity and Enhance Chemoefficacy in a Rat Model. <i>Chemotherapy</i> , 2018, 63, 284-292.	0.8	5
24	Routine assessment of the gut microbiome to promote preclinical research reproducibility and transparency. <i>Gut</i> , 2017, 66, 1869-1871.	6.1	3
25	Editorial Comment. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 155-156.	0.5	1